Stars Rally Together Again For Stand Up To Cancer ’ s Live Broadcast On September 7

LOS ANGELES– Stand Up To Cancer (SU2C), a division of the Entertainment Industry Foundation (EIF), is proud to announce that the Hollywood community is rallying together yet again to support the sixth biennial televised fundraising special. CBS will donate one hour of commercial-free primetime to broadcast the event on Friday, Sept. 7  from 8:00 – 9:00 PM ET/PT (7:00 – 8:00 PM CT). Mahershala Ali, Kathy Bates, Katie Couric, Jennifer Garner, Tony Hale, Marg Helgenberger, Ed Helms, Ken Jeong, Marlee Matlin, Matthew McConaughey, Maria Menounos, Jillian Michaels, Trevor Noah, Dak Prescott, Italia Ricci, Rob Riggle, Karla Souza, David Spade, Keith Urban, and Reese Witherspoon will all participate in this memorable event — marking 10 years since the first telecast and 10 years of SU2C’s lifesaving research achievements. Bradley Cooper will return as co-executive producer along with the renowned live-event producing team Done + Dusted, working again with the Stand Up To Cancer production team, after a successful partnership for the 2016 telecast. “As someone whose family has been significantly touched by cancer, I am proud to again have the privilege of co-executive producing this year’s Stand Up To Cancer telecast,” said Cooper. “This show reminds everyone that you are never alone… that there is a community of support out there when you need it most. That’s the power of SU2C. Most importantly, the telecast show...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health Only CBS Stand Up To Cancer Source Type: news

Related Links:

Publication date: Available online 19 April 2019Source: The American Journal of SurgeryAuthor(s): Tammy Ju, Lisbi Rivas, Kyle Kurland, Sheena Chen, Andrew Sparks, Paul P. Lin, Khashayar VaziriAbstractBackgroundTo identify trends in total and subtotal gastrectomy for middle and distal third gastric adenocarcinoma in the U.S.MethodsNCDB was queried for patients with stage 0-III middle or distal gastric adenocarcinoma treated with total or subtotal gastrectomy. Statistical analysis including cox proportional hazards model was performed to examine overall survival by stage.Results1,628(85%) underwent subtotal gastrectomy and 2...
Source: The American Journal of Surgery - Category: Surgery Source Type: research
CANCER symptoms vary depending on which part of the body is affected by a tumour. You may be at risk of a deadly tumour if you have this painful sign in your chest. Should you see a doctor?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Publication date: Available online 19 April 2019Source: Seminars in Cancer BiologyAuthor(s): Lingzhi Li, Zhuoyu Bi, Priya Wadgaonkar, Yongju Lu, Qian Zhang, Yao Fu, Chitra Thakur, Li Wang, Fei ChenAbstractAt present, the belief that genetic mutations control every aspect of tumorigenesis is still very popular. Even for the highly debated “bad luck” theory of cancers, it ascertained that random mutation of genes during the self-renewal of somatic stem cells is responsible for cancer initiation. Logically, most of the new therapeutic strategies so far, from molecular targeting to precision medicine or personalize...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 16 April 2019Source: Seminars in Cancer BiologyAuthor(s): Samanta Salvi, Massimiliano Bonafè, Sara BravacciniAbstractThe possibility that a receptor for androgen is expressed in Breast Cancer (BC) is fascinating given that the tumor is predominantly estrogen-dependent.The androgen receptor (AR) is emerging as a new marker and a potential new therapeutic target in the treatment of BC patients. The recent availability of selective AR inhibitors (e.g. bicalutamide, enzalutamide, apalutamide) approved for the treatment of prostate cancer has opened up the possibility to use them in BC ...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
We report a case of adult APML with amplification of RARα/PML fusion protein, a consequence of isoderivative 17 with duplication of normal chromosome 15 and 17 and Tp53 deletion on derivative 17. Immunophenotyping by flow cytometry, presence of pancytopenia and epistaxis helped classify the patient as APML. FISH was used for confirmation of the same and indicated involvement of additional abnormalities.
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research
Conclusions and Perspectives In this review, we have discussed important milestones from the early description of “Serum-sickness” as being due to antibodies directed against Neu5Gc epitopes all the way to the present-day therapeutic implications of these antibodies in cancer therapy. Some of these milestones have been represented in a concise timeline (Figure 6). While the “Xenosialitis” hypothesis is well-supported in the human-like mouse models, it has yet to be conclusively proven in humans. It remains to be seen if “Xenosialitis” plays a role in other uniquely-human diseases. FI...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
This study was supported by the Shanghai Sailing Program [grant number 17YF1425200, 2017]; Chinese National Natural Science Funding [grant number 81702249, 2017]; Science and Technology Commission of Shanghai Municipality [grant number 17511103403, 2017]; The funder has no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Conflict of Interest Statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Acknowledgments We acknowledge the ex...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Yi He†, Wenyong Long† and Qing Liu* Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China Super-enhancers (SEs) refer to large clusters of enhancers that drive gene expressions. Recent data has provided novel insights in elucidating the roles of SEs in many diseases, including cancer. Many mechanisms involved in tumorigenesis and progression, ranging from internal gene mutation and rearrangement to external damage and inducement, have been demonstrated to be highly associated with SEs. Moreover, translocation, formation, deletion, or duplication of SEs themselves co...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
In conclusion, osmotic burst of inflated complement-damaged cells may occur, but these bursts are most likely a consequence of metabolic collapse of the cell rather than the cause of cell death. The Complement Cell Death Mediator: A Concerted Action of Toxic Moieties Membrane pores caused by complement were first visualized by electron microscopy on red blood cell membranes as large ring structures (22). Similar lesions were viewed on E. coli cell walls (23). Over the years, ample information on the fine ultrastructure of the MAC that can activate cell death has been gathered (24) and has been recently further examined (...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusions: CAR T cell therapies have demonstrated the clinical benefits of harnessing our body's own defenses to combat tumor cells. Similar research is being conducted on lesser known modifications and gene-modified immune cells, which we highlight in this review. Introduction Chimeric antigen receptors and engineered T cell receptors (based on previously identified high affinity T cell receptors) function by redirecting T cells to a predefined tumor-specific (or tumor-associated) target. Most of these modifications use retroviral or lentiviral vectors to integrate the construct, and most of the receptors ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Clinical Trials | Colon Cancer | Colorectal Cancer | Funding | Fundraising | Grants | Health | Immunotherapy | Laboratory Medicine | Leukemia | Melanoma | Men | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Partnerships | Prostate Cancer | Science | Skin Cancer | Sports Medicine | Study